Invega Trinza

Schizophrenia, Schizoaffective Disorder, Antidepressants + 3 more
Treatment
20 Active Studies for Invega Trinza

What is Invega Trinza

PaliperidoneThe Generic name of this drug
Treatment SummaryPaliperidone is a drug used to treat schizophrenia. It works by blocking dopamine, serotonin, and other receptors in the brain. It was approved by the FDA in 2006 and is available in tablet form, as a monthly injection, a 3-month injection, or a twice-yearly injection.
Invegais the brand name
image of different drug pills on a surface
Invega Trinza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Invega
Paliperidone
2006
81

Effectiveness

How Invega Trinza Affects PatientsPaliperidone is an antipsychotic medicine made by Janssen Pharmaceutica. It is similar to the medicine risperidone but is more active once it is in the body. The exact way that it works is unknown, but it likely affects the body in a similar way as risperidone does.
How Invega Trinza works in the bodyPaliperidone is a drug used to treat schizophrenia. We don't know exactly how it works, but it likely works by blocking the effects of dopamine and serotonin in the brain. Blocking these two neurotransmitters can help reduce the symptoms of schizophrenia.

When to interrupt dosage

The prescribed dose of Invega Trinza is contingent upon the ascertained condition, including Therapeutic process, Schizophrenia and Mood stabilizing agents. The measure of dosage is contingent upon the technique of delivery outlined in the table below.
Condition
Dosage
Administration
Schizophrenia
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Schizoaffective Disorder
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Therapeutic procedure
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Therapeutic procedure
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Mood stabilizing agents
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular
Antidepressants
, 6.0 mg, 3.0 mg, 1.5 mg, 9.0 mg, 75.0 mg, 100.0 mg, 50.0 mg, 150.0 mg, 12.0 mg, 25.0 mg, 175.0 mg, 263.0 mg, 350.0 mg, 525.0 mg, 390.0 mg/mL, 780.0 mg/mL, 1170.0 mg/mL, 156.0 mg/mL, 234.0 mg/mL, 2730.0 mg/mL, 410.0 mg/mL, 546.0 mg/mL, 819.0 mg/mL, 750.0 mg/mL, 150.0 mg/mL, 1.5 mg/mg, 100.0 mg/mL, 500.0 mg/mL, 250.0 mg/mL, 263.0 mg/mL, 350.0 mg/mL, 525.0 mg/mL, 1750.0 mg/mL, 700.0 mg/mL, 1000.0 mg/mL, 1092.0 mg/mL, 1560.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Suspension, extended release - Intramuscular, Intramuscular, Suspension, extended release, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Injection, Injection - Intramuscular

Warnings

There are 20 known major drug interactions with Invega Trinza.
Common Invega Trinza Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Paliperidone.
Acepromazine
Major
Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Alfuzosin
Major
Paliperidone may increase the hypotensive activities of Alfuzosin.
Amisulpride
Major
Paliperidone may increase the antipsychotic activities of Amisulpride.
Aripiprazole lauroxil
Major
Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.
Invega Trinza Toxicity & Overdose RiskIf someone takes too much of the drug, they could become confused, have seizures, or experience abnormal head and neck movements, which may cause them to choke if they are made to throw up.
image of a doctor in a lab doing drug, clinical research

Invega Trinza Novel Uses: Which Conditions Have a Clinical Trial Featuring Invega Trinza?

221 active clinical trials are evaluating the potential of Invega Trinza in providing therapeutic benefit for Schizoaffective Disorder, Schizophrenia and Mood stabilizing agents.
Condition
Clinical Trials
Trial Phases
Mood stabilizing agents
0 Actively Recruiting
Antidepressants
0 Actively Recruiting
Schizoaffective Disorder
52 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1, Phase 3
Therapeutic procedure
0 Actively Recruiting
Schizophrenia
175 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1, Phase 4, Phase 1
Therapeutic procedure
0 Actively Recruiting

Invega Trinza Reviews: What are patients saying about Invega Trinza?

5Patient Review
8/6/2015
Invega Trinza for Schizophrenia
We started this medication for my son three years ago and he has not had to stay in the hospital since then. Prior to taking this medication, he was hospitalized about two times a year.
5Patient Review
8/9/2017
Invega Trinza for Schizophrenia
My husband had great results with this treatment.
3.7Patient Review
10/3/2019
Invega Trinza for Schizophrenia
I was on the sustenna formulation for about three years before switching to trinza as soon as it became available. I've been using it for approximately one year and am generally pleased with the results in terms of symptom control. That said, I still experience anxiety episodes a couple times each week.
2.7Patient Review
3/21/2019
Invega Trinza for Schizophrenia
My son saw good results for the first seven months of taking Invega Sustenna, but his doctor then switched him to Invega Trinza. Unfortunately, it seems to have stopped being effective after about a month and a half, so he's now supplementing with oral paliperidone and experiencing symptoms again. He wants to go back to the Invega Sustenna because the Trinza has just not been as effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about invega trinza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is INVEGA TRINZA used for?

"Paliperidone palmitate is an atypical antipsychotic that is available as a 3-month injection. It is indicated for the treatment of schizophrenia in patients who have been adequately treated with paliperidone palmitate for at least four months."

Answered by AI

How long does it take for INVEGA TRINZA to work?

"Low energy may take longer to improve, but don't be discouraged if it takes a few months to feel like your old self.

Your symptoms will improve over time, with some improvements happening quickly (within hours to days) and others happening gradually over the course of weeks to months. You may see quick improvements in your frustration and agitation levels, and your sleep and mood should improve within the first week. Your thinking will become more clear and organized over the course of 2-8 weeks, and your energy levels may take longer to improve, but this is normal. Don't be discouraged if it takes a few months to feel like your old self again."

Answered by AI

What is the difference between INVEGA SUSTENNA and INVEGA TRINZA?

"Invega Sustenna, Invega Trinza, and Invega Hayfera differ in the length of time they last in the body. Invega Sustenna lasts for 1 month, Invega Trinza lasts for 3 months, and Invega Hayfera lasts for 6 months and only needs to be given twice a year."

Answered by AI

How often is INVEGA TRINZA given?

"INVEGA TRINZA® should be initially taken once every three months, with possible adjustments every three months as needed based on efficacy or tolerability, within a range of 273 to 819 mg."

Answered by AI

Clinical Trials for Invega Trinza

Have you considered Invega Trinza clinical trials? We made a collection of clinical trials featuring Invega Trinza, we think they might fit your search criteria.
Have you considered Invega Trinza clinical trials? We made a collection of clinical trials featuring Invega Trinza, we think they might fit your search criteria.
Have you considered Invega Trinza clinical trials? We made a collection of clinical trials featuring Invega Trinza, we think they might fit your search criteria.